The case for & against
Bull & Bear analysis
Bullish
iTeos Therapeutics, Inc. (NASDAQ: ITOS) is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapy solutions. With a strategic emphasis on harnessing immune responses to combat tumor-induced immunosuppression, ITOS works on targeting key pathways related to immuno-oncology, including the adenosine and TIGIT pathways. Based in Cambridge, Massachusetts, with an R&D facility in Belgium, ITOS aims to leverage its scientific insights to make significant advancements in cancer treatment and address unmet medical needs in oncology.
Bull says
- ↑$899.8M cash as of 9/30/21 funds ops into 2026
- ↑GSK deal: $625M upfront plus up to $1.45B milestones
- ↑Initiated EOS-448 combos with pembrolizumab and Inupadenant
- ↑Targets adenosine and TIGIT pathways in niche IO market
- ↑Strong qualitative earnings yield, high ROE, positive momentum
Bear says
- ↓R&D expenses rose to $16.1M in Q3 2021 from $8.7M YoY
- ↓Any EOS-448/Inupadenant trial setback may shorten cash runway
- ↓Competes head-to-head with Merck, BMS, GSK, AZN, Novartis
- ↓Data miss risks turning optimism into a value trap
- ↓High volatility and elevated short interest reflect bearish sentiment
- ↓Operating costs outpace catalysts, pressuring near-term valuation
Earnings Call · Q1 2021 · Mgmt. Guidance
Updated 09-10-2026bullish
Transcript signals
Bull points
- we believe that doing monotherapy will help us to get a better understanding of the mechanism of adenosine receptor antagonist prostate cancer, and that could also help us to identify a specific subpopulation that would be more adapted to such treatment.
- the combination with pembrolizumab is additional added value. It would allow to explore, I would say, treatment which is chemo-free, which is also a significant expectation from the patient with prostate cancer, and could help us to differentiate our program compared to competitors.
- Based on the characterization of inupiaq demand, our research team has identified a new target, which has never been described explain your role in the adenosine pathway for cancer immunosuppression.
Bear points
- The net loss attributable to common shareholders was $13.5 million, or a net loss of $0.39 per basic and diluted share for the quarter ended March 31st, 2021, as compared to $6.5 million, or a net loss of $25.53 per basic and diluted share for the first quarter of 2020.
- We are still working on additional data because this assay also gives us, I would say, insight into a making fraction that has never been described so far for adenosine receptor antagonists, and this is the reason why we will disclose additional data later in the year or early next year.
Read full transcript analysis ›